What is Arthur M Lubitz?
Arthur M Lubitz operates as a premier Manhattan-based medical practice specializing in allergy, asthma, and immunology. With over three decades of clinical expertise, the practice distinguishes itself through the integration of advanced diagnostic testing and personalized treatment modalities, such as sublingual immunotherapy. By prioritizing operational efficiency and patient accessibility—exemplified by their same-day appointment model—the firm maintains a robust market position as a trusted provider for patients navigating complex immunological conditions in an urban environment.
How much funding has Arthur M Lubitz raised?
Arthur M Lubitz has raised a total of $160K across 1 funding round:
Debt
$160K
Debt (2021): $160K with participation from PPP
Key Investors in Arthur M Lubitz
PPP
Public-Private Partnership
What's next for Arthur M Lubitz?
The infusion of capital from this late-stage investment will likely be directed toward scaling the practice's technological infrastructure and enhancing patient care delivery systems. As the firm transitions into this next phase of growth, strategic priorities will likely include the adoption of cutting-edge medical technologies and the potential expansion of clinical capacity to meet the rising demand for specialized allergy care. By leveraging this financial backing, Arthur M Lubitz is poised to solidify its reputation as a leader in clinical immunology, ensuring that the practice remains at the forefront of patient-centric medical innovation while maintaining the high standards of care that have defined its multi-decade history.
See full Arthur M Lubitz company page
